{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:41:28Z","timestamp":1792708888214,"version":"4.5.0"},"reference-count":62,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,12,5]]},"abstract":"<jats:p>The past 40 years have witnessed major advances in defining the cytogenetic aberrations, mutational landscape, epigenetic profiles, and expression changes underlying hematological malignancies. Although it has become apparent that acute myeloid leukemia (AML) is highly heterogeneous at the molecular level, the standard framework for risk stratification guiding transplant practice in this disease remains largely based on pretreatment assessment of cytogenetics and a limited panel of molecular genetic markers, coupled with morphological assessment of bone marrow (BM) blast percentage after induction. However, application of more objective methodology such as multiparameter flow cytometry (MFC) has highlighted the limitations of morphology for reliable determination of remission status. Moreover, there is a growing body of evidence that detection of subclinical levels of leukemia (ie, minimal residual disease, MRD) using MFC or molecular-based approaches provides powerful independent prognostic information. Consequently, there is increasing interest in the use of MRD detection to provide early end points in clinical trials and to inform patient management. However, implementation of MRD assessment into clinical practice remains a major challenge, hampered by differences in the assays and preferred analytical methods employed between routine laboratories. Although this should be addressed through adoption of standardized assays with external quality control, it is clear that the molecular heterogeneity of AML coupled with increasing understanding of its clonal architecture dictates that a \u201cone size fits all\u201d approach to MRD detection in this disease is not feasible. However, with the range of platforms now available, there is considerable scope to realistically track treatment response in every patient.<\/jats:p>","DOI":"10.1182\/asheducation-2014.1.222","type":"journal-article","created":{"date-parts":[[2014,11,24]],"date-time":"2014-11-24T18:39:03Z","timestamp":1416854343000},"page":"222-233","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":45,"title":["Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for \u201cprime time\u201d?"],"prefix":"10.1182","volume":"2014","author":[{"given":"David","family":"Grimwade","sequence":"first","affiliation":[{"name":"Department of Medical & Molecular Genetics, King's College London School of Medicine, London, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie D.","family":"Freeman","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, University of Birmingham Medical School, Edgbaston, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2019111702374321300_B1","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.hoc.2011.09.018","article-title":"Diagnostic and prognostic value of cytogenetics in acute myeloid leukemia","volume":"25","author":"Grimwade","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"issue":"10","key":"2019111702374321300_B2","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrclinonc.2012.150","article-title":"The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach","volume":"9","author":"Cornelissen","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"2019111702374321300_B3","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N Engl J Med"},{"issue":"15","key":"2019111702374321300_B4","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1182\/blood-2012-03-419622","article-title":"A novel hierarchical prognostic model of AML solely based on molecular mutations","volume":"120","author":"Grossmann","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2019111702374321300_B5","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"key":"2019111702374321300_B6","unstructured":"National Comprehensive Cancer Network AML guideline\n          \n            http:\/\/www.nccn.org\/professionals\/physician gls\/f guidelines.asp#aml"},{"issue":"22","key":"2019111702374321300_B7","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"N Engl J Med"},{"issue":"29","key":"2019111702374321300_B8","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1200\/JCO.2011.41.5323","article-title":"Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia","volume":"30","author":"Inaba","year":"2012","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111702374321300_B9","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/blood-2012-02-408336","article-title":"Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group","volume":"120","author":"Loken","year":"2012","journal-title":"Blood"},{"issue":"32","key":"2019111702374321300_B10","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1200\/JCO.2013.49.1753","article-title":"Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia","volume":"31","author":"Freeman","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111702374321300_B11","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1182\/blood-2011-08-363291","article-title":"Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia","volume":"119","author":"Buccisano","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2019111702374321300_B12","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.beha.2010.06.007","article-title":"The role of multiparameter flow cytometry for disease monitoring in AML","volume":"23","author":"Kern","year":"2010","journal-title":"Best Pract Res Clin Haematol"},{"issue":"31","key":"2019111702374321300_B13","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1200\/JCO.2012.45.9628","article-title":"High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON\/SAKK AML 42A study","volume":"31","author":"Terwijn","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111702374321300_B14","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/bmt.2012.139","article-title":"Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia","volume":"48","author":"Buckley","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2019111702374321300_B15","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/bjh.12358","article-title":"Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation","volume":"162","author":"Campana","year":"2013","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111702374321300_B16","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood.V98.6.1746","article-title":"Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification","volume":"98","author":"San Miguel","year":"2001","journal-title":"Blood"},{"issue":"7","key":"2019111702374321300_B17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.it.2012.02.010","article-title":"A deep profiler's guide to cytometry","volume":"33","author":"Bendall","year":"2012","journal-title":"Trends Immunol"},{"issue":"6","key":"2019111702374321300_B18","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nbt.2594","article-title":"viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia","volume":"31","author":"Amir","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"1","key":"2019111702374321300_B19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/cytob.21134","article-title":"Tumor heterogeneity makes AML a \u201cmoving target\u201d for detection of residual disease","volume":"86","author":"Zeijlemaker","year":"2014","journal-title":"Cytometry B Clin Cytom"},{"issue":"9","key":"2019111702374321300_B20","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2002-10-3064","article-title":"Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia","volume":"101","author":"Sievers","year":"2003","journal-title":"Blood"},{"issue":"10","key":"2019111702374321300_B21","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1182\/blood-2013-06-506725","article-title":"Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission","volume":"122","author":"Walter","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2019111702374321300_B22","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1073\/pnas.1324297111","article-title":"Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission","volume":"111","author":"Corces-Zimmerman","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2019111702374321300_B23","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ccr.2014.01.031","article-title":"Functional heterogeneity of genetically defined subclones in acute myeloid leukemia","volume":"25","author":"Klco","year":"2014","journal-title":"Cancer Cell"},{"issue":"7488","key":"2019111702374321300_B24","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature13038","article-title":"Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia [published correction appears in Nature. 2014;508(7496):420]","volume":"506","author":"Shlush","year":"2014","journal-title":"Nature"},{"issue":"9","key":"2019111702374321300_B25","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1182\/blood-2009-08-239749","article-title":"Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment","volume":"115","author":"Westers","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2019111702374321300_B26","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1053\/j.seminoncol.2008.04.009","article-title":"Development of minimal residual disease-directed therapy in acute myeloid leukemia","volume":"35","author":"Freeman","year":"2008","journal-title":"Semin Oncol"},{"issue":"2","key":"2019111702374321300_B27","doi-asserted-by":"crossref","first-page":"e22943","DOI":"10.4161\/onci.22943","article-title":"Can immunotherapy specifically target acute myeloid leukemic stem cells?","volume":"2","author":"Snauwaert","year":"2013","journal-title":"OncoImmunology"},{"issue":"5","key":"2019111702374321300_B28","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/leu.2012.312","article-title":"Azacitidine fails to eradicate leukemic stem\/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia","volume":"27","author":"Craddock","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"2019111702374321300_B29","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1172\/JCI41495","article-title":"Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD\/SCID\/IL2R\u03b3c-deficient mice","volume":"121","author":"Sarry","year":"2011","journal-title":"J Clin Invest"},{"issue":"10","key":"2019111702374321300_B30","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1182\/blood-2009-02-206565","article-title":"Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(\u2212) fraction","volume":"115","author":"Taussig","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2019111702374321300_B31","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ccr.2010.12.012","article-title":"Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia","volume":"19","author":"Goardon","year":"2011","journal-title":"Cancer Cell"},{"issue":"11","key":"2019111702374321300_B32","doi-asserted-by":"crossref","first-page":"e78897","DOI":"10.1371\/journal.pone.0078897","article-title":"Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells","volume":"8","author":"Schuurhuis","year":"2013","journal-title":"PLoS ONE"},{"issue":"9","key":"2019111702374321300_B33","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1200\/JCO.2010.31.8121","article-title":"Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia","volume":"29","author":"Walter","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111702374321300_B34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/cyto.b.20429","article-title":"Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses","volume":"76","author":"Loken","year":"2009","journal-title":"Cytometry B Clin Cytom"},{"key":"2019111702374321300_B35","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1038\/bcj.2013.27","article-title":"Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting","volume":"3","author":"Feller","year":"2013","journal-title":"Blood Cancer J"},{"issue":"2","key":"2019111702374321300_B36","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/bjh.12614","article-title":"hMICL and CD123 in combination with a CD45\/CD34\/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia","volume":"164","author":"Roug","year":"2014","journal-title":"Br J Haematol"},{"issue":"9","key":"2019111702374321300_B37","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1182\/blood-2010-09-303685","article-title":"Towards individualized follow up in adult acute myeloid leukemia in remission","volume":"117","author":"Hokland","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2019111702374321300_B38","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/gcc.22100","article-title":"NUP98-NSD1 fusion in association with FLT3-ITD mutation identifies a prognostically relevant subgroup of pediatric acute myeloid leukemia patients suitable for monitoring by real time quantitative PCR","volume":"52","author":"Akiki","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"issue":"12","key":"2019111702374321300_B39","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"issue":"12","key":"2019111702374321300_B40","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","article-title":"Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using \u2018real-time\u2019 quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe Against Cancer program","volume":"17","author":"Beillard","year":"2003","journal-title":"Leukemia"},{"issue":"24","key":"2019111702374321300_B41","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111702374321300_B42","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1182\/blood-2008-04-150250","article-title":"Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"113","author":"Sanz","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2019111702374321300_B43","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3324\/haematol.10734","article-title":"Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia","volume":"92","author":"Santamar\u00eda","year":"2007","journal-title":"Haematologica"},{"issue":"22","key":"2019111702374321300_B44","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1200\/JCO.2008.20.1533","article-title":"Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy","volume":"27","author":"Grimwade","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111702374321300_B45","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111702374321300_B46","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.beha.2014.04.002","article-title":"Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia?","volume":"27","author":"Grimwade","year":"2014","journal-title":"Best Pract Res Clin Haematol"},{"issue":"23","key":"2019111702374321300_B47","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1200\/JCO.2010.28.6468","article-title":"Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia","volume":"28","author":"Corbacioglu","year":"2010","journal-title":"J Clin Oncol"},{"issue":"14","key":"2019111702374321300_B48","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1182\/blood-2012-06-435669","article-title":"Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial","volume":"120","author":"Yin","year":"2012","journal-title":"Blood"},{"issue":"12","key":"2019111702374321300_B49","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1182\/blood-2012-10-462879","article-title":"Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia","volume":"121","author":"Jourdan","year":"2013","journal-title":"Blood"},{"issue":"20","key":"2019111702374321300_B50","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1182\/blood-2012-11-468348","article-title":"MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial","volume":"121","author":"Zhu","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2019111702374321300_B51","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/sj.leu.2404149","article-title":"Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations","volume":"20","author":"Gorello","year":"2006","journal-title":"Leukemia"},{"issue":"11","key":"2019111702374321300_B52","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2009-03-213389","article-title":"Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML","volume":"114","author":"Schnittger","year":"2009","journal-title":"Blood"},{"issue":"19","key":"2019111702374321300_B53","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1200\/JCO.2011.35.0371","article-title":"Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group","volume":"29","author":"Kr\u00f6nke","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111702374321300_B54","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/blood-2012-10-461749","article-title":"The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML","volume":"122","author":"Shayegi","year":"2013","journal-title":"Blood"},{"issue":"31","key":"2019111702374321300_B55","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1200\/JCO.2009.22.4865","article-title":"Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study","volume":"27","author":"Cilloni","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111702374321300_B56","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/bjh.12181","article-title":"Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of WT1 expression","volume":"160","author":"Pozzi","year":"2013","journal-title":"Br J Haematol"},{"issue":"10","key":"2019111702374321300_B57","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/leu.2013.219","article-title":"Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet\/MPN&MPNr-EuroNet (COST action BM0902) study","volume":"27","author":"Jovanovic","year":"2013","journal-title":"Leukemia"},{"issue":"7","key":"2019111702374321300_B58","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/gcc.21955","article-title":"Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations","volume":"51","author":"Thol","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"issue":"1","key":"2019111702374321300_B59","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/leu.2013.239","article-title":"Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease","volume":"28","author":"Kohlmann","year":"2014","journal-title":"Leukemia"},{"issue":"10","key":"2019111702374321300_B60","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/nmeth.2633","article-title":"Absolute quantification by droplet digital PCR versus analog real-time PCR","volume":"10","author":"Hindson","year":"2013","journal-title":"Nat Methods"},{"issue":"2","key":"2019111702374321300_B61","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jmoldx.2013.10.007","article-title":"Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR","volume":"16","author":"Jennings","year":"2014","journal-title":"J Mol Diagn"},{"issue":"1","key":"2019111702374321300_B62","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/cytob.21140","article-title":"Residual disease in AML, a target that can move in more than one direction","volume":"86","author":"Loken","year":"2014","journal-title":"Cytometry B Clin Cytom"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2014\/1\/222\/64454\/bep00114000222.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2014\/1\/222\/64454\/bep00114000222.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T07:38:08Z","timestamp":1573976288000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2014\/1\/222\/20477\/Defining-minimal-residual-disease-in-acute-myeloid"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,5]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2014.1.222","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,5]]}}}